AxoGen’s revenue increased from $2 million in 2012’s second quarter to $2.9 million. Company executives attributed the gain to an increased number of facilities using AxoGen’s products.
The company’s net loss jumped from $3.1 million to $6.9 million, due in part to increased interest costs. The company paid $1.8 million in interest added to the note after having paid no interest the year prior.
More Articles on Devices:
Aesculap’s Quintex Anterior Cervical Spine Plating System Now Available
SpineVision Names Ken Yamada as US Subsidiary COO
Orthozon Technologies Launches Lumiere Retractor for Minimally Invasive Discectomy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
